mRNA Vaccines and Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

mRNA Vaccines and Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

  • May 2022 •
  • 147 pages •
  • Report ID: 6280645 •
  • Format: PDF
The global mRNA vaccines and therapeutics market reached a value of US$ 54.37 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 40.55 Billion by 2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Messenger Ribonucleic Acid (mRNA) refers to a single protein-coding gene in the genome that acts as a basis for protein synthesis within the cells. mRNA vaccines and therapeutics combine the desirable immunological properties and are prepared in laboratories using mammalian cells. Some of the common types of vaccines and therapeutics include self-amplifying, non-replicating, in vivo self-replicating and in vitro dendritic cell non-replicating mRNA. They are injected into the body to trigger virus-detecting immune sensors and produce viral antigen proteins within the cells. This aids in enhancing the body’s immunity by improving B- and T-cell responses.

The rising prevalence of medical ailments, such as diabetes, tuberculosis, cancer and cardiovascular diseases (CVDs), is one of the key factors driving the growth of the market. The increasing demand for therapeutic medicines and vaccines for Ebola, influenza, Human Immunodeficiency Virus (HIV) and other viral infections is also providing a boost to the market growth. In comparison to conventional medicines, mRNA vaccines and therapeutics are developed using advanced technologies that are more effective against pathogens, have higher potency, enhanced immunogenicity and are relatively more cost-effective. Additionally, improvements in the lipid nanoparticle formulations for in-vivo systemic delivery of mRNA are also creating a positive outlook for the market. Pharmaceutical companies are investing in mRNA technologies as they can combine multiple molecules into a therapeutic medicine, which is acting as another major growth-inducing factor. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with improvements in the healthcare technologies, are projected to drive the market further.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global mRNA vaccines and therapeutics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on vaccine type, treatment type, vaccine manufacturing, application and end-user.

Breakup by Vaccine Type:
Self-amplifying mRNA-Based Vaccines
Conventional Non-Amplifying mRNA-Based Vaccines

Breakup by Treatment Type:
Bioengineered Vaccine
Gene Therapy
Gene Transcription
Cell Therapy
Monoclonal Antibody
Others

Breakup by Vaccine Manufacturing:
In-House
Out-Sourced

Breakup by Application:
Cancer
Infectious Disease
Gene Editing
Protein Replacement

Breakup by End-User:
Hospitals and Clinics
Research Organizations
Others

Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Arcturus Therapeutics Inc., BioNTech SE, CureVac AG, eTheRNA immunotherapies NV, ethris GmbH, GlaxoSmithKline PLC, Moderna Therapeutics Inc., Translate Bio Inc., Argos Therapeutics, Inc., Sangamo Therapeutics Inc. and Pfizer Inc, etc.



Key Questions Answered in This Report:

How the global mRNA vaccines and therapeutics market will perform in the coming years?
What will be the key regional markets?
What will be the impact of COVID-19 on the global mRNA vaccines and therapeutics market?
What will be the key vaccine types in the market?
What will be the key treatment types in the market?
What will be the key manufacturing types in the market?
What will be the applications in the market?
What will be the key end-use segments in the market?
What would be the various stages in the value chain of the industry?
What will be the key driving factors and challenges in the industry?
What will be the structure of the global mRNA vaccines and therapeutics market and who will be the key players?
What would be the degree of competition in the industry?